S869 TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY

Autor:	T. E. Witzig, F. Burrows, M.J. Roncero Vidal, R. Advani, Michael R. Kurman, Lubomir Sokol, Ana Marin Niebla, L. Kessler, C. Scholz, Robert Curry, M. Jose Terol, James Bolognese, Miguel A. Piris, R. de Ona Navarrete, F. Foss, Marta Rodríguez, V. Mishra, Eva Domingo-Domenech, Antonio Gualberto, W.S. Kim, Eric N. Jacobsen, A. Rodriguez Izquierdo, F. de la Cruz Vicente, Matthew R. Janes, D Caballero
Rok vydání:	2019
Předmět:	business.industry Cancer research medicine Phases of clinical research Tipifarnib Hematology Open label medicine.disease business Refractory Angioimmunoblastic T-cell Lymphoma Peripheral T-cell lymphoma medicine.drug
Zdroj:	HemaSphere. 3:389
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000561756.23393.6d
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::69f49228a57513758adb28f8c341efe9 https://doi.org/10.1097/01.hs9.0000561756.23393.6d Zobrazit plný text záznamu Plný text